Sign up to save your podcasts
Or
Share BioNTech's Richardson on Drug Pipeline
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
BioNTech's Richardson on Drug Pipeline
BioNTech has a broad and diversified cancer drug pipeline extending well beyond mRNA based approaches. Sam Fazeli, Senior Health Care Analyst, speaks to Ryan Richardson, Chief Strategy Officer, who explains the company’s approach to drug development, hopes for drug launches and what sets it apart from rivals.
See omnystudio.com/listener for privacy information.
View all episodes
By Bloomberg
5
33 ratings
BioNTech has a broad and diversified cancer drug pipeline extending well beyond mRNA based approaches. Sam Fazeli, Senior Health Care Analyst, speaks to Ryan Richardson, Chief Strategy Officer, who explains the company’s approach to drug development, hopes for drug launches and what sets it apart from rivals.
See omnystudio.com/listener for privacy information.
More shows like Vanguards of Health Care by Bloomberg Intelligence
View all
Freakonomics Radio
32,082 Listeners
Masters in Business
2,173 Listeners
Odd Lots
1,855 Listeners
a16z Podcast
1,087 Listeners
Up First from NPR
56,444 Listeners
Today, Explained
10,229 Listeners
The Readout Loud
325 Listeners
Here's Why
67 Listeners
The Prof G Pod with Scott Galloway
5,458 Listeners
BioCentury This Week
33 Listeners
The Ezra Klein Show
16,144 Listeners
Biotech Hangout
20 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
510 Listeners
Prof G Markets
1,330 Listeners
Think Big, Buy Small
36 Listeners